Evidence map›Paper›PMID 31101004›Full record

ReviewThe journal of headache and pain2019

Optimising migraine treatment: from drug-drug interactions to personalized medicine.

Leda Marina Pomes, Martina Guglielmetti, Enrico Bertamino, Maurizio Simmaco, Marina Borro, Paolo Martelletti

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The journal of headache and pain, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Reaching the Nadir of Medication Overuse in Chronic Migraine.International journal of environmental research and public health · 2022
    Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Leda Marina PomesResidency Program in Laboratory Medicine, Gabriele d'Annunzio University, Chieti, Italy.
Martina GuglielmettiRegional Referral Headache Centre, Sant'Andrea Hospital, Rome, Italy.
Enrico BertaminoResidency Program in Hygiene and Preventive Medicine, Sapienza University of Rome, Rome, Italy.
Maurizio SimmacoDepartment of Neurosciences, Mental Health and Sensory Organs, Sapienza University of Rome, Rome, Italy.
Marina BorroDepartment of Neurosciences, Mental Health and Sensory Organs, Sapienza University of Rome, Rome, Italy.
Paolo MartellettiDepartment of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy. paolo.martelletti@uniroma1.it.ORCID http://orcid.org/0000-0002-6556-4128

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Migraine is the most disabling and expensive chronic disorders, the etiology of which is still not fully known. The neuronal systems, (glutammatergic, dopaminergic, serotoninergic and GABA-ergic) whose functionality is partly attributable to genetically determined factors, has been suggested to play an important role. The treatment of acute attacks and the prophylactic management of chronic forms include the use of different category of drugs, and it is demonstrated that not each subject has the same clinical answer to them. The reason of this is to be searched in different functional capacity and quantity of phase I enzymes (such as different isoforms of CYP P450), phase II enzymes (such as UDP-glucuronosyltransferases), receptors (such as OPRM1 for opioids) and transporters (such as ABCB1) involved in the metabolic destiny of each drug, all of these dictated by DNA and RNA variations. The general picture is further exacerbated by the need for polytherapies, often also to treat comorbidities, which may interfere with the pharmacological action of anti-migraine drugs. Personalized medicine has the objective of setting the optimal therapies in the light of the functional biochemical asset and of the comorbidities of the individual patient, in order to obtain the best clinical response. Novel therapeutic perspectives in migraine includes biotechnological drugs directed against molecules (such as CGRP and its receptor) that cause vasodilatation at the peripheral level of the meningeal blood vessels and reflex stimulation of the parasympathetic system. Drug-drug interactions and the possible competitive metabolic destiny should be studied by the application of pharmacogenomics in large scale. Drug-drug interactions and their possible competitive metabolic destiny should be studied by the application of pharmacogenomics in large scale.

Indexed as

Analgesics, OpioidAntidepressive Agents, TricyclicAnti-Inflammatory Agents, Non-SteroidalCalcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor AntagonistsDrug InteractionsHumansMigraine DisordersPharmacogeneticsPrecision MedicineTryptaminesAnalgesics, OpioidAntidepressive Agents, TricyclicAnti-Inflammatory Agents, Non-SteroidalCalcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide Receptor AntagonistsTryptaminesAnti-migraine drugsCGRP monoclonal antibodiesDitansGepantsPersonalized medicinePharmacogenomicPolytherapies

Identifiers

PMID31101004
PMCPMC6734220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.